Evidence map›Paper›PMID 36688635›Full record

ArticleMicrobiology spectrum2023

Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis.

Shilah Bonnett, Jo-Ann Jee, Somsundaram Chettiar, Yulia Ovechkina, Aaron Korkegian, Eric Greve, Joshua Odingo, Tanya Parish

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Novel 3-Aminothieno[2,3-ACS medicinal chemistry letters · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shilah BonnettTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Jo-Ann JeeTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Somsundaram ChettiarTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Yulia OvechkinaTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Aaron KorkegianTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Eric GreveCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Joshua OdingoTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.ORCID 0000-0001-7507-0423
Infectious Disease Research Institute · US

Funding

High throughput assays to detect inhibition of a key M. tuberculosis proteaseR01AI095652 · NIAID · ACCESS TO ADVANCED HEALTH INSTITUTE · PI PARISH, TANYA · 2013 to 2015
$1.1M
High throughput assays to detect inhibition of a key M. tuberculosis proteaseR56AI095652 · NIAID · ACCESS TO ADVANCED HEALTH INSTITUTE · PI PARISH, TANYA · 2011 to 2011
$396k
NIAID NIH HHS R01 AI095652NIAID NIH HHS R56 AI095652
6 · The paper itself

Abstract

We identified an amino-benzothiazole scaffold from a whole-cell screen against recombinant Mycobacterium tuberculosis under expressing the essential signal peptidase LepB. The seed molecule had 2-fold higher activity against the LepB hypomorph. Through a combination of purchase and chemical synthesis, we explored the structure-activity relationship for this series; 34 analogs were tested for antitubercular activity and for cytotoxicity against eukaryotic cells. We identified molecules with improved potency and reduced cytotoxicity. However, molecules did not appear to target LepB directly and did not inhibit protein secretion. Key compounds showed good permeability, low protein binding, and lack of CYP inhibition, but metabolic stability was poor with short half-lives. The seed molecule showed good bactericidal activity against both replicating and nonreplicating bacteria, as well as potency against intracellular M. tuberculosis in murine macrophages. Overall, the microbiological properties of the series are attractive if metabolic stability can be improved, and identification of the target could assist in the development of this series.

Indexed as

Mycobacterium tuberculosisTuberculosisAnimalsAntitubercular AgentsMiceMicrobial Sensitivity TestsProtein BindingStructure-Activity RelationshipAntitubercular Agentsantibioticantitubercularbactericidal activitydrug discoveryprotein secretiontuberculosis

Identifiers

PMID36688635
PMCPMC9927457
OpenAlexW4317752038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.